🇺🇸 FDA
Pipeline program

Luvometinib

WCSH-NCP-SS-LCH-2026

Unknown small_molecule active

Quick answer

Luvometinib for Langerhans Cell Histiocytosis (LCH) is a Unknown program (small_molecule) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Indication
Langerhans Cell Histiocytosis (LCH)
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials